I am a big fan of this COVID immunity paper from @Anto_Berto . This was the first paper to longitudinally track viral loads AND virus-specific T cells in COVID patients quantitatively in the same study, from early time points. 🧵
Since immune responses (and viral replication) are exponential processes, it is hard to determine meaningful correlations between immune responses and viral control without time courses, starting from very early.
Because this study tracked T cell responses and viral loads together, from early times after infection, the interpretations are more likely to be correct than more commonly available studies with a single time point or much later timepoints.
The study also observed a relationship between peak viral load and duration of infection. That connects this study with the larger literature of studies that tracked viral loads and disease severity but not T cell responses.
This study only had 12 patients, so it will be important to have similar immunological studies from other labs, and other geographical locations and cohort characteristics (as acknowledged by the authors), but it is the first study of its kind and a valuable contribution.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
In a new pre-print by the excellent @McGuire_Lab , they report a big jump in neutralizing antibodies after a single COVID RNA vaccine immunization (Pfizer or Moderna).
Penny Moore and Alex Sigal and colleagues now report on antibodies from AZ ChAdOx vaccinated people, and there was a dramatic loss of function against the B1351 variant. It appears to be more than a 20x reduction. A complete loss of neutralization in most individuals (~80%).
First, what to think of the antibody neutralization loss?
It is much steeper than reported by multiple groups elsewhere for COVID19 cases or other COVID vaccines. Multiple labs reported ~2x drop in neutralization of B1351 or related virus, with antibodies from vaccinated people
SIX successful COVID-19 vaccines! SIX! Three just in the past week! Extraordinary. The newest one is the Russian (Rus) adenoviral (Ad) vector COVID vaccine. The clinical trial data look really good at face value. 🧵